BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24368611)

  • 1. Geographic Variation in Oxaliplatin Chemotherapy and Survival in Patients With Colon Cancer.
    Panchal JM; Lairson DR; Chan W; Du XL
    Am J Ther; 2016; 23(3):e720-9. PubMed ID: 24368611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
    Panchal JM; Lairson DR; Chan W; Du XL
    Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.
    Mack CD; Carpenter W; Meyer AM; Sanoff H; Stürmer T
    Cancer; 2012 Jun; 118(11):2925-34. PubMed ID: 22072441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
    Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
    Hsiao FY; Mullins CD; Onukwugha E; Pandya N; Hanna N
    J Am Geriatr Soc; 2011 Sep; 59(9):1717-23. PubMed ID: 21831168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.
    Sanoff HK; Carpenter WR; Stürmer T; Goldberg RM; Martin CF; Fine JP; McCleary NJ; Meyerhardt JA; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Clin Oncol; 2012 Jul; 30(21):2624-34. PubMed ID: 22665536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.
    Sanoff HK; Carpenter WR; Freburger J; Li L; Chen K; Zullig LL; Goldberg RM; Schymura MJ; Schrag D
    Cancer; 2012 Sep; 118(17):4309-20. PubMed ID: 22294436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.
    Zuckerman IH; Rapp T; Onukwugha E; Davidoff A; Choti MA; Gardner J; Seal B; Mullins CD
    J Am Geriatr Soc; 2009 Aug; 57(8):1403-10. PubMed ID: 19563521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
    Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
    Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
    Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer.
    Iwashyna TJ; Lamont EB
    J Clin Oncol; 2002 Oct; 20(19):3992-8. PubMed ID: 12351596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.
    Sundararajan V; Mitra N; Jacobson JS; Grann VR; Heitjan DF; Neugut AI
    Ann Intern Med; 2002 Mar; 136(5):349-57. PubMed ID: 11874307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.
    Peixoto RD; Kumar A; Speers C; Renouf D; Kennecke HF; Lim HJ; Cheung WY; Melosky B; Gill S
    Clin Colorectal Cancer; 2015 Mar; 14(1):25-30. PubMed ID: 25465343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospital lymph node examination rates and survival after resection for colon cancer.
    Wong SL; Ji H; Hollenbeck BK; Morris AM; Baser O; Birkmeyer JD
    JAMA; 2007 Nov; 298(18):2149-54. PubMed ID: 18000198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy.
    Mack CD; Glynn RJ; Brookhart MA; Carpenter WR; Meyer AM; Sandler RS; Stürmer T
    Pharmacoepidemiol Drug Saf; 2013 Aug; 22(8):810-8. PubMed ID: 23296544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of Adjuvant Oxaliplatin for Colon Cancer: Insights From Routine Clinical Practice.
    Satkunam N; Wei X; Biagi JJ; Nanji S; Booth CM
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1548-1554. PubMed ID: 27956539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using surveillance, epidemiology and end results (SEER)-Medicare data.
    Hanna NN; Onukwugha E; Choti MA; Davidoff AJ; Zuckerman IH; Hsu VD; Mullins CD
    Colorectal Dis; 2012 Jan; 14(1):48-55. PubMed ID: 21689262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.